Updated on 15 February 2013
FDA grants orphan drug status to Eisai cancer drug lenvatinib
Singapore: Eisai announced that the US FDA has granted orphan drug designation to its investigational drug lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer.
The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug that has the potential for the treatment, diagnosis or prevention of a rare disease or disorder that affects fewer than 200,000 people in the US.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
